Literature DB >> 20494946

Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents.

Vance L Albaugh1, Thomas C Vary, Olga Ilkayeva, Brett R Wenner, Kevin P Maresca, John L Joyal, Steven Breazeale, Tedd D Elich, Charles H Lang, Christopher J Lynch.   

Abstract

Patients taking atypical antipsychotics are frequented by serious metabolic (eg, hyperglycemia, obesity, and diabetes) and cardiac effects. Surprisingly, chronic treatment also appears to lower free fatty acids (FFAs). This finding is paradoxical because insulin resistance is typically associated with elevated not lower FFAs. How atypical antipsychotics bring about these converse changes in plasma glucose and FFAs is unknown. Chronic treatment with olanzapine, a prototypical, side effect prone atypical antipsychotic, lowered FFA in Sprague-Dawley rats. Olanzapine also lowered plasma FFA acutely, concomitantly impairing in vivo lipolysis and robustly elevating whole-body lipid oxidation. Increased lipid oxidation was evident from accelerated losses of triglycerides after food deprivation or lipid challenge, elevated FFA uptake into most peripheral tissues (∼2-fold) except heart, rises in long-chain 3-hydroxylated acyl-carnitines observed in diabetes, and rapid suppression of the respiratory exchange ratio (RER) during the dark cycle. Normal rises in RER following refeeding, a sign of metabolic flexibility, were severely blunted by olanzapine. Increased lipid oxidation in muscle could be explained by ∼50% lower concentrations of the negative cytoplasmic regulator of carnitine palmitoyltransferase I, malonyl-CoA. This was associated with loss of anapleurotic metabolites and citric acid cycle precursors of malonyl-CoA synthesis rather than adenosine monophosphate-activated kinase activation or direct ACC1/2 inhibition. The ability of antipsychotics to lower dark cycle RER in mice corresponded to their propensities to cause metabolic side effects. Our studies indicate that lipocentric mechanisms or altered intermediary metabolism could underlie the FFA lowering and hyperglycemia (Randle cycle) as well as some of the other side effects of atypical antipsychotics, thereby suggesting strategies for alleviating them.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20494946      PMCID: PMC3245588          DOI: 10.1093/schbul/sbq053

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  52 in total

1.  Intracerebroventricular leptin regulates hepatic cholesterol metabolism.

Authors:  Sonya Vanpatten; George B Karkanias; Luciano Rossetti; David E Cohen
Journal:  Biochem J       Date:  2004-04-15       Impact factor: 3.857

Review 2.  Diabetes: mellitus or lipidus?

Authors:  E Shafrir; I Raz
Journal:  Diabetologia       Date:  2003-03-14       Impact factor: 10.122

Review 3.  Fuel selection in human skeletal muscle in insulin resistance: a reexamination.

Authors:  D E Kelley; L J Mandarino
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

4.  alpha-Ketoacid dehydrogenase complexes and respiratory fuel utilisation in diabetes.

Authors:  P J Randle
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

5.  Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B.

Authors:  U J Tietge; A Bakillah; C Maugeais; K Tsukamoto; M Hussain; D J Rader
Journal:  J Lipid Res       Date:  1999-11       Impact factor: 5.922

6.  Malonyl-CoA content and fatty acid oxidation in rat muscle and liver in vivo.

Authors:  D Chien; D Dean; A K Saha; J P Flatt; N B Ruderman
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-08       Impact factor: 4.310

7.  Increased efficiency of fatty acid uptake contributes to lipid accumulation in skeletal muscle of high fat-fed insulin-resistant rats.

Authors:  Bronwyn D Hegarty; Gregory J Cooney; Edward W Kraegen; Stuart M Furler
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

8.  Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis.

Authors:  V L Albaugh; J G Judson; P She; C H Lang; K P Maresca; J L Joyal; C J Lynch
Journal:  Mol Psychiatry       Date:  2010-03-23       Impact factor: 15.992

9.  The antipsychotic drug sulpiride does not affect bodyweight in male rats. Is insulin resistance involved?

Authors:  Trino Baptista; Anny Lacruz; Ximena Pàez; Luis Hernàndez; Serge Beaulieu
Journal:  Eur J Pharmacol       Date:  2002-06-28       Impact factor: 4.432

10.  Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance.

Authors:  Jie An; Deborah M Muoio; Masakazu Shiota; Yuka Fujimoto; Gary W Cline; Gerald I Shulman; Timothy R Koves; Robert Stevens; David Millington; Christopher B Newgard
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

View more
  35 in total

1.  Metabolic Impairments Precede Changes in Hunger and Food Intake Following Short-Term Administration of Second-Generation Antipsychotics.

Authors:  Karen L Teff; Karl Rickels; Erica Alshehabi; Michael R Rickels
Journal:  J Clin Psychopharmacol       Date:  2015-10       Impact factor: 3.153

2.  Chronic treatment with olanzapine increases adiposity by changing fuel substrate and causes desensitization of the acute metabolic side effects.

Authors:  Elodie M Girault; Bruno Guigas; Anneke Alkemade; Ewout Foppen; Mariëtte T Ackermans; Susanne E la Fleur; Eric Fliers; Andries Kalsbeek
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-05       Impact factor: 3.000

3.  Chronic olanzapine treatment decreases arachidonic acid turnover and prostaglandin E₂ concentration in rat brain.

Authors:  Yewon Cheon; Jee-Young Park; Hiren R Modi; Hyung-Wook Kim; Ho-Joo Lee; Lisa Chang; Jagadeesh S Rao; Stanley I Rapoport
Journal:  J Neurochem       Date:  2011-09-20       Impact factor: 5.372

4.  Exploring mechanisms of increased cardiovascular disease risk with antipsychotic medications: Risperidone alters the cardiac proteomic signature in mice.

Authors:  Megan Beauchemin; Ramaz Geguchadze; Anyonya R Guntur; Kathleen Nevola; Phuong T Le; Deborah Barlow; Megan Rue; Calvin P H Vary; Christine W Lary; Katherine J Motyl; Karen L Houseknecht
Journal:  Pharmacol Res       Date:  2019-12-23       Impact factor: 7.658

5.  Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.

Authors:  Robin H Isaacson; Juliane I Beier; Nicholas Kh Khoo; Bruce A Freeman; Zachary Freyberg; Gavin E Arteel
Journal:  J Nutr Biochem       Date:  2020-04-08       Impact factor: 6.048

6.  Preliminary Examination of Olanzapine and Diet Interactions On Metabolism in a Female Macaque.

Authors:  Oleg Varlamov; Paul Kievit; Kenny Phu; Arubala P Reddy; Charles T Roberts; Cynthia L Bethea
Journal:  J Endocrinol Diabetes       Date:  2014

Review 7.  Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.

Authors:  Karen L Teff; Sangwon F Kim
Journal:  Physiol Behav       Date:  2011-06-12

8.  Second-generation antipsychotics cause a rapid switch to fat oxidation that is required for survival in C57BL/6J mice.

Authors:  Candice M Klingerman; Michelle E Stipanovic; Mohammad Bader; Christopher J Lynch
Journal:  Schizophr Bull       Date:  2013-01-17       Impact factor: 9.306

9.  Chronic clozapine reduces rat brain arachidonic acid metabolism by reducing plasma arachidonic acid availability.

Authors:  Hiren R Modi; Ameer Y Taha; Hyung-Wook Kim; Lisa Chang; Stanley I Rapoport; Yewon Cheon
Journal:  J Neurochem       Date:  2012-12-06       Impact factor: 5.372

10.  Olanzapine activates hepatic mammalian target of rapamycin: new mechanistic insight into metabolic dysregulation with atypical antipsychotic drugs.

Authors:  Robin H Schmidt; Jenny D Jokinen; Veronica L Massey; K Cameron Falkner; Xue Shi; Xinmin Yin; Xiang Zhang; Juliane I Beier; Gavin E Arteel
Journal:  J Pharmacol Exp Ther       Date:  2013-08-07       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.